SCHEMBL2147013

SCHEMBL2147013

O=C(O)c1c[nH]nc1O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL163291 0.76
SCHEMBL69630 0.76 ALDH1A1 (0.39)
SCHEMBL14438179 0.76 TSHR (0.44)
SCHEMBL16665480 0.74
SCHEMBL27902718 0.74
SCHEMBL357764 0.74
SCHEMBL14399039 0.74
SCHEMBL16297103 0.74
SCHEMBL263529 0.74
SCHEMBL21621359 0.74 PLK1 (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210323960-A1 FUSED TRI-CYCLIC COMPOUND AS PDE3/PDE4 DUAL INHIBITOR CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2021-10-21 US disclosed
EP-3822272-A1 FUSED TRI-CYCLIC COMPOUND AS PDE3/PDE4 DUAL INHIBITOR Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) 2021-05-19 EP disclosed
WO-2020011254-A1 FUSED TRI-CYCLIC COMPOUND AS PDE3/PDE4 DUAL INHIBITOR 正大天晴药业集团股份有限公司 2020-01-16 WO disclosed
CN-109956929-A Hete rocyclic derivatives, preparation method, pharmaceutical composition and application 上海迪诺医药科技有限公司 2019-07-02 CN disclosed
WO-2019113476-A2 PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2019-06-13 WO disclosed
CN-109803962-A Modulators of cystic fibrosis transmembrane conductance regulator proteins, pharmaceutical compositions, methods of treatment, and methods for making the modulators 弗特克斯药品有限公司 2019-05-24 CN disclosed
CN-104844578-B 5 membered heterocyclic amides and relevant compound H.隆德贝克有限公司 2018-06-19 CN disclosed
US-20160264567-A1 SUBSTITUTED SULFONAMIDE COMPOUNDS GENENTECH, INC. (US) 2016-09-15 US disclosed
WO-2016128529-A1 1-(HET)ARYLSULFONYL-(PYRROLIDINE OR PIPERIDINE)-2-CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRPA1 ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2016-08-18 WO disclosed
US-9227971-B2 Pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors MERCK SHARP & DOHME CORP. (US) 2016-01-05 US disclosed
US-9227971-B2 Pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors MERCK SHARP & DOHME CORP. (US) 2016-01-05 US disclosed
US-9227971-B2 Pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors MERCK SHARP & DOHME CORP. (US) 2016-01-05 US disclosed
CN-104844578-A 5-MEMBERED HETEROCYCLIC AMIDES AND RELATED COMPOUNDS NEUROGEN CORP 2015-08-19 CN disclosed
CN-101711245-B 5-membered heterocyclic amides and related compounds LUNDBECK & CO AS H 2015-03-25 CN disclosed
US-20120322791-A1 PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS MERCK SHARP & DOHME LLC 2012-12-20 US disclosed
US-20120322791-A1 PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS MERCK SHARP & DOHME LLC 2012-12-20 US disclosed
US-20120322791-A1 PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS MERCK SHARP & DOHME LLC 2012-12-20 US disclosed
WO-2011090935-A1 PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS MERCK SHARP & DOHME CORP. (US) 2011-07-28 WO disclosed
WO-2011090935-A1 PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS MERCK SHARP & DOHME CORP. (US) 2011-07-28 WO disclosed
CN-1610673-A Method for producing pyrazole compound TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2005-04-27 CN disclosed